



Primary Care





References

1. NICE Clinical Guideline CG148 Urinary incontinence in neurological disease: assessment and management. <https://www.nice.org.uk/guidance/cg148>
2. NICE Clinical Guideline NG123 urinary incontinence and pelvic organ prolapse
3. NICE Technology Appraisal Guidance TA290 Mirabegron for treating symptoms of overactive bladder. <https://www.nice.org.uk/guidance/ta290/chapter/2-The-technology> [Accessed 13.2.20]
4. Summary of Product Characteristics BOTOX® 100 Units (last updated on the eMC: 12.06.19) <https://www.medicines.org.uk/emc/product/859/smpc> [accessed 20 August 2019]
5. Summary of Product Characteristics BOTOX® 200 Units (last updated on the eMC: 12.06.19) <https://www.medicines.org.uk/emc/product/436/smpc> [accessed 20 August 2019]
6. Jefferson, K (North Bristol Trust) (2020) Evidence Review: Solifenacin and Mirabegron Combination Therapy for Overactive Bladder. (attached supporting document)